Michael Charlton to Liver Diseases
This is a "connection" page, showing publications Michael Charlton has written about Liver Diseases.
Connection Strength
1.484
-
Usefulness of Liver Transplantation in the Elderly: The Converging Impact of Risk and Benefit. Gastroenterology. 2016 Feb; 150(2):306-9.
Score: 0.474
-
Hepatocyte tails. Clin Gastroenterol Hepatol. 2006 May; 4(5):564-5.
Score: 0.243
-
Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr. 2006 01; 136(1 Suppl):295S-8S.
Score: 0.237
-
Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant. 2003 Jul; 3(7):885-90.
Score: 0.200
-
Protein metabolism and liver disease. Baillieres Clin Endocrinol Metab. 1996 Oct; 10(4):617-35.
Score: 0.125
-
Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther. 2010 Sep; 32(6):776-86.
Score: 0.081
-
Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10(6):1420-7.
Score: 0.080
-
Mandatory Hepatology Education for Internal Medicine Residents: Long-Term Effects and Implications for Workforce Needs. Hepatol Commun. 2021 11; 5(11):1953-1963.
Score: 0.044